Betül YAVUZ KELEŞ, Burcu ÖNDER, Kadriye ÖNEŞ, Meltem VURAL

Evaluation of the effects of β1-selective beta-blockers on bone mineral density and fracture risk in postmenopausal women

Background/aim: β1-selective beta-blockers (BBs) are sympatholytic agents, and discerning their effects on bone health would be ofgreat importance. This study aimed to investigate the influence of β1-selective BBs on bone mineral density (BMD) and fracture risk.Materials and methods: This study included postmenopausal women who used β1-selective BBs (BB group) and control group.Sociodemographic characteristics, BMD and previous fragility fractures were recorded. Additionally, the 10-year probability of a majorosteoporotic and hip fracture was calculated using the fracture risk assessment tool (FRAX).Results: A total of 60 participants were included in the study. L1-4 and L2-4 BMD values were significantly higher in BB group thancontrol group (P = 0.015 and P = 0.025, respectively). Moreover, T-scores of lumbar and femur total were significantly higher in theBB group. Two patients in BB and 6 patients in control group had previous fragility fracture. No statistically significant intergroupdifference was noted regarding FRAX.Conclusion: Based on our results, β1-selective BB usage was associated with higher BMD at the lumbar region in postmenopausalwomen.

PDF

___

1. Black DM, Rosen CJ. Postmenopausal osteoporosis. The New England Journal of Medicine 2016; 374 (3): 254-262. doi: 10.1056/NEJMcp1513724
2. Jackson RD, Mysiw WJ. Insights into the epidemiology of postmenopausal osteoporosis: the Women’s Health Initiative. Seminars in Reproductive Medicine 2014; 32 (6): 454-62. doi: 10.1002/art.38611
3. Diab DL, Watts NB. Postmenopausal osteoporosis. Current Opinion in Endocrinology, Diabetes and Obesity 2013; 20 (6): 501-509. doi: 10.1097/01.med.0000436194.10599.94
4. Qui Y, Yang W, Wang Q,Yan S, Li B et al. Osteoporosis in postmenopausal women in this decade: a bibliometric assessment of current research and future hotspots. Archives of Osteoporosis 2018; 13 (1): 1-8. doi: 10.1007/s11657-018-0534-5
5. Hanley DA, Brown JP, Tenenhouse A, Olszynski WP, Ioannidis G et al. Associations among disease conditions, bone mineral density, and prevalent vertebral deformities in men and women 50 years of age and older: cross-sectional results from the Canadian Multicentre Osteoporosis Study. Journal of Bone and Mineral Research 2003; 18 (4): 784-790. doi: 10.1359/ jbmr.2003.18.4.784
6. Puth MT, Klaschik M, Schmid M, Weckbecker K, Münster E. Prevalence and comorbidity of osteoporosis- a cross-sectional analysis on 10,660 adults aged 50 years and older in Germany. BMC Musculoskeletal Disorders 2018; 19 (1): 144.
7. Hant FN, Bolster MB. Drugs that may harm bone: mitigating the risk. Cleveland Clinic Journal of Medicine 2016; 83 (4): 281- 288. doi: 10.3949/ccjm.83a.15066
8. Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L et al. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002;111 (3): 305-317. doi: 0.1016/s0092-8674(02)01049-8
9. Reid IR, Lucas J, Wattie D, Horne A, Bolland M et al. Effects of a beta-blocker on bone turnover in normal postmenopausal women: a randomized controlled trial. The Journal of Clinical Endocrinology & Metabolism 2005; 90 (9): 5212-5216. doi: 10.1210/jc.2005-0573
10. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000; 100 (2): 197-207. doi: 10.1016/s0092-8674(00)81558-5
11. Solomon DH, Ruppert K, Zhao Z,Lian YJ, Kuo IH et al. Bone mineral density changes among women initiating blood pressure lowering drugs: a SWAN cohort study. Osteoporosis International 2016; 27 (3): 1181-1189. doi: 10.1007/s00198-015-3332-6
12. Ağaçayak KS, Güven S, Koparal M, Güneş N, Atalay Y et al. Longterm effects of antihypertensive medications on bone mineral density in men older than 55 years. Clinical Intervations in Aging 2014; 9: 509-513. doi: 10.2147/CIA.S60669
13. Toulis KA, Anastasilakis AD, Polyzos SA, Makras P. Targeting the osteoblast: approved and experimental anabolic agents for the treatment of osteopororosis. Hormones (Athens) 2011;10 (3): 174-195. doi: 10.14310/horm.2002.1308
14. Togari A, Arai M, Mizutani S, Koshihara Y, Nagatsu T. Expression of mRNAs for neuropeptide receptors and beta-adrenergic receptors in human osteoblasts and human osteogenic sarcoma cells. Neuroscience Letters 1997; 233 (2-3): 125-128. doi: 10.1016/ s0304-3940(97)00649-6
15. Toulis KA, Hemming K, Stergianos S, Nirantharakumar K, Bilezikian J. β-adrenergic receptor antagonists and fracture risk: a meta-analysis of selectivity, gender, and site-specific effects. Osteoporosis International 2014; 25 (1): 121-129. doi: 10.1007/ s00198-013-249
16. Sosa M, Saavedra P, Gomez de Tejeda MJ, Mosquera J, PérezCano R et al. Beta blocker use associated with fragility farctures in postmenopausal women with coronary hearth disease. Aging Clinical and Experimental Research 2011; 23 (2):112-117. doi: 10.3275/7041
17. Yang S, Nguyen ND, Eisman JA, Nguyen TV. Association between beta-blocker use and fracture risk: the Dubbo Osteoporosis Epidemiology Study. Bone 2012; 51 (5): 969- 974. doi: 10.1016/j.bone.2010.10.170
18. Song HJ, Lee J, Kim YJ, Jung SY, Kim HJ et al. Beta1 selectivity of beta-blockers and reduced risk of fractures in elderly hypertension patients. Bone 2012; 51 (6): 1008-1015. doi: 10.1016/j.bone.2012.08.126
19. Pérez-Castrillón JL, Vega G, Abad L, Sanz A, Mendo M et al. Effect of beta-blockers on bone mass and biomechanical parameters of the femoral neck in males with acute myocardial infarction. Joint Bone Spine 2007; 74 (3): 259-262. doi: 10.1016/j.jbspin.2006.09.015
20. Barzilay JI, Davis BR, Pressel SL, Barzilay JI, Davis BR et al.The impact of antihypertensive medications on bone mineral density and fracture risk. Current Cardiology Reports 2017; 19 (9): 1-9. doi: 10.1007/s11886-017-0888-0
21. Zang Y, Tan Q, Ma X, Zhao X, Lei W. Osteogenic actions of metoprolol in an ovariectomized rat model of menopause. Menopause 2016; 23 (9): 1019-1025. doi: 10.1097/ GME.0000000000000680
22. WHO Scientific Group on Research on the Menopause in the 1990s (1994 : Geneva, Switzerland) & World Health Organization.World Health Organization technical report series 1996; 866: 1-107.
23. Tuzun S, Eskiyurt N, Akarirmak U, Saridogan M, Senocak M et al. Turkish Osteoporosis Society. Incidence of hip fracture and prevalence of osteoporosis in Turkey: the FRACTURK study. Osteoporosis International 2012; 23 (3): 949-955. doi: 10.1007/ s00198-011-1655-5
24. Koçyiğit F, Acar M, Baydar M, Kuyucu E, Koçyiğit A. Would FRAX define the high fracture risk if the patients were evaluated the day before hip fracture? Turkish Journal of Physical Medicine and Rehabilitation 2015; 61 (4): 339-343. doi : 10.5152/tftrd.2015.32549
25. Turker S, Karatosun V, Gunal I. Beta-blockers increase bone mineral density. Clinical Orthopaedics and Related Research 2006; 443: 73-74. doi: 10.1097/01. blo.0000200242.52802.6d
26. Farr JN, Charkoudian N, Barnes JN, Monroe DG, McCready LK et al. Relationship of sympathetic activity to bone microstructure, turnover, and plasma osteopontin. The Journal of Clinical Endocrinology & Metabolism 2012; 97 (11): 4219- 4227. doi: 10.1210/jc.2012-2381.
27. Lambert E, Phillips S, Tursunalieva A, Eikelis N, Sari C et al. Inverse association between sympathetic nervous system activity and bone mass in middle aged overweight individuals. Bone 2018; 111: 123-128. doi: 10.1016/j. bone.2018.03.025
28. Khosla S, Drake MT, Volkman TL, Thicke BS, Achenbach SJ et al. Sympathetic β1 adrenergic signaling contributes to regulation of bone metabolism. Journal of Clinical Investigation 2018; 128 (11): 4832-4842. doi: 10.1172/JCI122151
29. Tuzun S, Eskiyurt N, Akarirmak U, Saridogan M, Johansson H et al. The impact of a FRAX-based intervention threshold in Turkey: The FRAX-TURK study. Archieves of Osteoporosis 2012; 7: 229-235. doi: 10.1007/s11657-012-0101-4
30. OlmezSarikaya N, KaparYavasi S, Tan G, Satiroglu S, Yildiz AH et al. Agreement between FRAX scores calculated with and without bone mineral density in women with osteopenia in Turkey. Clinical Rheumatology 2014; 33 (12): 1785-1789. doi: 10.1007/s10067-014-2491-8